Page 1

v / core pharma Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF Webinar will be held today at 15:00 CET ( 9:00 am EST ) Digital therapeutics expert Jessica Shull joins Vicore to drive DTX program ● ● Gothenburg , May 4 , 2021 - Vicore Pharma Holding AB ( publ ) ( " Vicore " ) , a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis ( IPF ) , today announces the signing of an agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic ( DTX ) built on the " Alex DTX Platform " . Vicore will hold a webinar at 15:00 CET ( 9 AM EST ) today to outline the strategic importance and operational details of the new program . The agreement with Alex Therapeutics marks the initiation of a new clinical program for Vicore ( VP04 ) - the joint development and commercialization of a clinically validated digital therapeutic ( DTX ) will provide cognitive behavioral therapy ( CBT ) for patients suffering from IPF . Under the agreement , Vicore will own all rights to VP04 in exchange for an upfront payment to Alex Therapeutics of 8.1 MSEK ( 1 MUSD ) , plus potential milestone payments and royalties on sales . VP04 expands Vicore's existing therapeutic programs in IPF and other severe respiratory diseases . The digital therapeutic will be designed to provide CBT to IPF patients , in parallel to routine consultations with medical professionals , to help improve their quality of life and support them through the psychological impacts of disease and its diagnosis . Working closely with patient groups and healthcare providers , Vicore and Alex Therapeutics expect to begin the clinical trial of VP04 in 2022 . " The VP04 program is part of Vicore's goal of addressing the totality of unmet medical needs in IPF , " said Carl - Johan Dalsgaard , CEO of Vicore . " While our highly promising VP01 and VP02 programs target the underlying causes and major physical symptoms of the disease , VP04 will address the psychological impact patients diagnosed with IPF often experience . We are very pleased to work with an experienced co - development partner like Alex Therapeutics to advance the clinical validation of VP04 and bring therapeutic solutions to IPF patients that address several dimensions of their disease . " To drive the VP04 program , Vicore has recently recruited Jessica Shull as Head of Digital Therapeutics . She brings more than 20 years ' experience in the development and adoption of digital healthcare technologies and has provided expertise on digital health best practices and policy for the WHO and the Digital Therapeutics Alliance . Vicore Pharma Holding AB ( publ ) | Kronhusgatan 11 , SE - 411 05 Gothenburg , Sweden Phone : +46 ( 0 ) 31 78 80 560 | VAT nr SE556680380401 | www.vicorepharma.com